Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.
Saved in:
| Title: | Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. |
|---|---|
| Authors: | Fang, Yu1,2,3 (AUTHOR), Su, Ning1,2,4 (AUTHOR), Zou, Qihua1,2 (AUTHOR), Cao, Yi1,2 (AUTHOR), Xia, Yi1,2 (AUTHOR), Tang, Linquan2,5 (AUTHOR), Tian, Xiaopeng1,2 (AUTHOR), Liu, Panpan1,2 (AUTHOR), Cai, Qingqing1,2 (AUTHOR) caiqq@sysucc.org.cn |
| Source: | BMC Medicine. 11/7/2023, Vol. 21 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 173470915 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Fang%2C+Yu%22">Fang, Yu</searchLink><relatesTo>1,2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Su%2C+Ning%22">Su, Ning</searchLink><relatesTo>1,2,4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zou%2C+Qihua%22">Zou, Qihua</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cao%2C+Yi%22">Cao, Yi</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xia%2C+Yi%22">Xia, Yi</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tang%2C+Linquan%22">Tang, Linquan</searchLink><relatesTo>2,5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tian%2C+Xiaopeng%22">Tian, Xiaopeng</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Panpan%22">Liu, Panpan</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cai%2C+Qingqing%22">Cai, Qingqing</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> caiqq@sysucc.org.cn</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22BMC+Medicine%22">BMC Medicine</searchLink>. 11/7/2023, Vol. 21 Issue 1, p1-10. 10p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=173470915 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12916-023-03140-x Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 10 StartPage: 1 Titles: – TitleFull: Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fang, Yu – PersonEntity: Name: NameFull: Su, Ning – PersonEntity: Name: NameFull: Zou, Qihua – PersonEntity: Name: NameFull: Cao, Yi – PersonEntity: Name: NameFull: Xia, Yi – PersonEntity: Name: NameFull: Tang, Linquan – PersonEntity: Name: NameFull: Tian, Xiaopeng – PersonEntity: Name: NameFull: Liu, Panpan – PersonEntity: Name: NameFull: Cai, Qingqing IsPartOfRelationships: – BibEntity: Dates: – D: 07 M: 11 Text: 11/7/2023 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 17417015 Numbering: – Type: volume Value: 21 – Type: issue Value: 1 Titles: – TitleFull: BMC Medicine Type: main |
| ResultId | 1 |